Compugen Ltd (CGEN) - Comprehensive Stock Analysis & Investment Research
Deep dive into Compugen Ltd's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Compugen Ltd Investment Summary
When evaluating whether Compugen Ltd (CGEN) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Compugen Ltd (CGEN) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $222 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Compugen Ltd's revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Compugen Ltd along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Compugen Ltd is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Compugen Ltd (Stock Symbol: CGEN) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Compugen Ltd's leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Compugen Ltd...
Sector & Industry Analysis
In-depth sector dynamics and industry context for Compugen Ltd...
Revenue & Growth Analysis
Compugen Ltd generates annual revenues of $145 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Compugen Ltd...
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Compugen Ltd...
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Compugen Ltd...
Strategic Market Position
Compugen Ltd strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Compugen Ltd competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company shows positive operational efficiency through free cash flow generation of $63 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.
Asset Utilization Efficiency
Asset turnover ratio of 0.93x indicates solid asset utilization efficiency appropriate for many manufacturing or mixed business models. This level suggests the company generates meaningful revenue from its asset base while maintaining necessary capital investments for operations.